Albumin Administration in CKD Patients

Introduction to Albumin Use in CKD

The National Kidney Foundation guidelines discuss reducing urinary albumin excretion as a treatment goal in CKD management, but this refers to preventing albumin loss through the kidneys, not replacing it with IV albumin 1, 2, 3

Reduction in urinary protein and albumin excretion is a fundamental management goal in CKD, with reductions playing important roles in slowing disease progression 1, 3
In patients with ≥300 mg/g urinary albumin, a reduction of 30% or greater is recommended to slow CKD progression, achieved through ACE inhibitors, ARBs, SGLT2 inhibitors, and other medications - not through albumin infusion 2, 4, 5
The American Diabetes Association recommends achieving this reduction through medications such as ACE inhibitors, ARBs, SGLT2 inhibitors, and other medications, with a strength of evidence classified as high 2, 4, 6